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Background: As demand for infertility services by older women continues to grow, because achievable in vitro
fertilization (IVF) outcomes are widely underestimated, most fertility centers do not offer maximal treatment options
with use of autologous oocytes. Limited data suggest that clinical IVF outcomes in excess of what the American
Society for Reproductive Medicine (ASRM) considers “futile” can, likely, be achieved up to at least age 45 years.
Methods: In an attempt to point out an evolving demographic trend in IVF, we here report our center’s IVF data for
2010-2012 and national U.S. data for 1997-2010. Though our center’s data are representative of only one IVF center’s
patients, they, likely, are unique since they probably represent the most adversely selected IVF patient population ever
reported and, thus, are predictive of future demographic trends. In addition we performed a systematic review of the
literature on the subject based on PubMed, Medline and Google Scholar searches till year-end 2013. The literature search
was performed using key words and phrases relevant to fertility treatments in older women.
Results: As demonstrated by our center’s patient demographics and national U.S. data, IVF centers are destined to
treat increasingly adversely selected patients. Despite our center’s already extremely adversely selected patient
population, age-specific IVF cycle outcomes in women above age 40 years, nevertheless, exceeded criteria for
“futility” by the ASRM and widely quoted outcome expectations in the literature for patient ages. Age 43 discriminates
between better and poorer clinical pregnancy and live birth rates.
Conclusions: “Graying” of the infertility populations in the developed world, a problem with potentially far-reaching
medical and societal consequences, has so far been only insufficiently addressed in the literature. As women’s
postmenopausal life spans already exceed postmenarcheal life spans at the start of the 20th century, the “graying”
of infertility services can be expected to further accelerate, no longer as in recent decades bringing only women
in their 40s into maternity wards but also women in their 50s and 60s. Medicine and society better get ready for
this revolution.
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Women above age 40 in the United States (U.S.) now rep-
resent the proportionally fastest growing age group having
children [1,2]. Potential medical and societal consequences
have found little attention in the medical literature, even
though a recent study once again offered convincing
evidence for the importance of age as a predictor of
failure to achieve live birth [3].* Correspondence: ngleicher@thechr.com
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unless otherwise stated.Because favorable patients now usually conceive rela-
tively quickly with in vitro fertilization (IVF), unfavorable
patients accumulate disproportionally in IVF centers. This
trend is further aggravated by above noted new reality
in the U.S. that older and older women are trying to
conceive.
Since our center for at least five years has been serving
primarily as a “center of last resort” for patients who
previously have failed IVF cycles elsewhere, our center
experience, likely, is predictive of where the practice of
IVF is destined to go over the coming decades.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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trends, our center’s 2010-2012 IVF outcome data, obtained
in a uniquely adversely selected patient population, to
assess outcome expectations, considering current practice
patterns, for women above age 40 years. We, in addition,
conducted a systemic search of the published literature on
this subject.
This presentation, therefore, primarily is not meant as a
presentation of original data but as a review of preliminary
existing data, which may point towards where IVF prac-
tice, likely, is destined to go over the next two decades.
Methods
IVF cycle outcomes
Our center’s IVF cycles, under a federally mandated law,
are annually reported to the Centers for Disease Control
(CDC) and voluntarily to the American Society for Repro-
ductive Medicine (ASRM)/Society for Assisted Reproductive
Technologies (SART).
In addition, every cycle is entered into the center’s
anonymized electronic research database, which served
as one source for here reported center data for 2012 IVF
cycles, together with the center’s annual reports to CDC
and ASRM/SART. 2013 outcome data were not yet
complete by the time of this report.
Our center’s patient population
Our center’s IVF experience should be of special interest
because of the patient population in which these out-
comes were achieved. Based on review of 2010 and 2011
published CDC and ASRM/SART outcome reporting data,
our center, proportionally, has been serving the largest per-
centage of women above age 42 years amongst all reporting
ART centers in the U.S. Other adverse selection parameters
for our center’s patient population are, however, not public
since they are not reported to either CDC and/or ASRM/
SART. Figures 1A and B demonstrate that our center’s
patient population, indeed, does likely reflect the most
adverse selection criteria of any reported IVF center in
the U.S., if not worldwide.
Figure 1A demonstrated mean and median ages of our
center’s IVF patient population between 2006-2012. As
the figure demonstrates, starting in 2010, our center
experienced a significant increase in patient age, which
even before already demonstrated a median population
age around 38 years. Since 2010 the median age has,
however, further increased to above age 40, with 2012
data suggesting that median age may soon reach age 41.
The “graying” of the center’s patient population is,
however, not only demonstrated by increasing age. As
Figure 1B demonstrates, concomitantly, the patients’
anti-Müllerian hormone (AMH) levels at presentation
significantly declined, indicating increasingly poor func-
tional ovarian reserve (FOR) of treated patients. Before2010, median AMH values hovered around 0.80 ng/mL,
already considered below favorable outcome levels for
women with low FOR [4]; yet, starting in 2010, median
AMH levels progressively decreased, reaching a nadir
in 2012 below 0.40 ng/mL, with preliminary 2013 data
(not shown) suggesting further declines.
Concomitantly, in our center’s 2012 annual CDC/SART
submissions, 13.8% of all fresh IVF cycles occurred in
women at ages 41-42 years, 20.6% at ages 43-44 years and
12.6% in women above age 46 years. This means that
47.0% of all fresh cycles involved women above age 41 and
33.2% of cycle women above age 43 years.
Considering these demographic data, it is not surprising
that only 10.1% of fresh cycles were followed up by a
frozen-thawed cycle during 2012 since women of advanced
age and with low FOR rarely produce enough oocytes/
embryos for subsequent thaw cycles. Yet, despite per-
formance of so many fresh IVF cycles in significantly
aged women, still, in addition, 18.3% of all fresh cycles
were donor egg cycles.
Further documentation of our center’s adverse patient
selection is the fact that between 2010-2012 in each year
over 85% of newly presenting patients to our center had
previously been in infertility treatments elsewhere and
had failed at least one IVF cycle attempt. Most of these
patients, indeed, had failed multiple IVF cycles, often at
a number of different centers. In addition, the number
of new long-distance patients, defined as patients from
outside the larger New York City Tristate area, has been
persistently increasing over the last five years, and in
2012 for the first time exceeded 60% of the centers total
new patient population. Approximately two-third of long-
distance patients come from the rest of the U.S. and
Canada, and the rest from overseas.
Here presented data demonstrate that our center’s
current population during 2012 in more than half of all
cases was of very advanced female age and/or suffered
from very low FOR. While such extreme patient charac-
teristics, currently, are not yet the norm at other IVF
centers, trends in developed countries go into the same
direction, as young and uncomplicated IVF patients quickly
conceive, while older and more poor prognosis patients
accumulate.
Systematic literature review
We searched PubMed, MEDLINE® and Google Scholar
databases for multiple key words and phrases, referring
to < fertility > and < fertility treatments > in < older women >
or at < advanced age>, including specific end points, like <
spontaneous pregnancies>, <pregnancy rates>, <in vitro
fertilization (IVF)>, <intrauterine insemination (IUI)>, <mis-
carriages>, <pregnancy loss>, <aneuploidy>, <medical
complications of pregnancy>, <age related medical com-
plications of pregnancy>, etc.
Figure 1 Our center’s patient characteristics, years 2006-2012. A. Mean and median age of patients in years 2006-2012 (in years). B. Mean
and median AMH values (ng/mL) in years 2006-2012.
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author (NG) and then reviewed by the three other authors
(VAK, AW, DHB).
This search failed to reveal even a single clinical trial
addressing fertility treatments in “older” women (>age
40 - 42 years), and also did not demonstrate even a
single review on the subject. Whatever limited data
are available, are here presented.Institutional Review Board (IRB)
Our patients sign at initial consultation, as part of a uni-
versal HIPAA consent form, a statement that allows use of
data from their medical records for reporting purposes to
CDC, ASRM/SART and for research purposes, as long as
their medical data remain confidential and their identity
remains protected. Both conditions were met here. Since
utilized data in here presented study only utilized anon-
ymized statistical data sets, it did not require further IRB
approval.Results
Our center’s 2010-2012 IVF outcome data
The center’s annual 2010-2012 IVF outcome data are
presented in Table 1. IVF outcomes are presented by
“intent to treat”, which means with reference point cycle
start. Considering how adversely selected here reported
patients are, this is important to note. Moreover, as
noted under “Materials and Methods”, a large majority
of patients presenting to our center have failed prior IVF
cycles elsewhere, often multiple cycles. Here reported
233 IVF cycles in most patients, therefore, followed prior
failed IVF cycles elsewhere. In addition, a good number
of here reported IVF cycles also represent repeat cycles
at our center. IVF treatment outcomes, therefore, should
at each age be significantly better than here reported if
only first IVF cycles were to be considered. Such an
analysis is, however, in here presented patient population
not possible.
As Table 1 demonstrates, up to and inclusive of age
42 years, live birth rates are even in such an adversely
Table 1 Our center’s 2010 - 2012 age-specific clinical IVF















*“Intent to treat” reflects denominator of per cycle start for each age group.
A total of 233 IVF cycles are reported. Because of an ~20% cycle cancellation
rate before embryo transfer, reports based on patients reaching embryo
transfer of at least 1 embryo would demonstrate ~ 20% higher clinical
pregnancy and live birth rates.
**Miscarriages reflect only established clinical pregnancies, confirmed by
ultrasound by presence of at least one intrauterine gestational sac. Chemical
and ectopic pregnancies are not considered in here presented data.
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with age 43 years, there is a significant drop off in both
clinical pregnancies and live births, as previously reported
by our group for earlier years [5]. Above, and including
age 46 years, pregnancy and delivery chances appear negli-
gible, even though in 2013 our center established two, at
this point ongoing clinical pregnancies, in women in their
46th year, which considering a small denominator, would
reflect a respectable live birth rate if both pregnancies
reach delivery (data not shown). Between 2010 – 2012
selected women up to age 53 were treated at our center,
as Table 1 demonstrates.
It is also important to note that in women with still
regular menses, at our center less than 20% fail to reach
retrieval and/or transfer. This relative low cycle cancellation
rate is based on our center’s policy to go to retrieval even
with single follicles, unless patients object or patients are
not already on maximal ovarian stimulation.
Likely, because of dehydroepiandrosterone (DHEA)
supplementation, which at our center is routine in women
with low FOR, miscarriage rates in even very adversely
selected patients have in the past been only 15.1% [6].
Since publication of this study, the degree of adverse
selection of patients at the center has, however, further
increased (Figures 1A&B). During 2011-2012, miscarriage
rates have, therefore, been in the 20.0-23.0% range. Table 1
demonstrates that miscarriages occurred primarily in the
oldest patients. These data concur with our earlier report,
which demonstrated that positive effects of DHEA on
miscarriage rates progressively increase after age 35 but,
of course, still increase with advancing female age [6].
Though overall modest, pregnancy rates obtained in a
highly adversely selected patient population at our center,
thus, clearly, at least up to and including age 42 but, likely,up to and including age 45 years, appear superior to the
predominant opinions in the profession as to what is
achievable in older women. Except for an outlier study by
Ninimäki et al. [7], they also appear superior to studies we
were able to discover in the literature on the subject (see
below). They, of course, also exceed the definitions of the
Ethics Committee of the ASRM for “futility” [8].
Our center’s IVF outcomes before 2012 have been
widely published [5,6,9-15]. We, therefore, conclude that,
based on clinical as well as ethical consideration, currently
available data under appropriate informed consents do
support a more proactive treatment of older women than
is currently the prevailing practice in the U.S. and Europe.
This argument appears further supported by the previ-
ously noted observation that even better outcomes than
reported here can be expected in less adversely selected
patients at older ages. Finally, unless the profession initi-
ates more active treatment of older women, it is unlikely
that maximal possible progress will be made in treating
such women. In medicine, only practice “makes perfect”.
As important success of oocyte donation has become
in offering maternity to older women, every egg dona-
tion, nevertheless, in at least some ways still represents
treatment failures in a case of infertility. Rising numbers
of oocyte donation cycles, as witnessed in many countries
around the world, including the U.S., therefore, at least
partially are a reflection of our profession’s failure in
helping many older women to conceive with use of
autologous oocytes.
What our center’s IVF outcome data are based on
Progress in treating older women is continuous. For
example, it only recently became known that at all ages
low FOR is associated with low androgen levels [13-15],
and that normal androgen levels (i.e., levels encountered
in young women) are essential for early stages of follicle
maturation [16,17]. We, therefore now pre-supplement
older women with dehydroepiandrosterone (DHEA) in
attempts to raise testosterone (T) levels [18]. Pregnancy
chances in IVF depend on the degree of improvement in
T levels after DHEA supplementation in such patients
[13-15]. Indeed, we learned not to initiate IVF cycles in
older women until T levels are in approximately the
upper one-third of normal range or slightly above.
We also learned that so-called low-intensity cycles
(“mini-IVF” or mild stimulation cycles) even in women
with normal FOR produce inferior outcomes in compari-
son to standard IVF cycles [19,20]. Though a prospective
clinical trial on this subject remains to be conducted,
they, therefore, can be expected to produce even poorer
outcomes in women with low FOR. In older women
our center, therefore, practically universally only utilizes
high dose gonadotropin stimulation in microdose-agonist
cycles.
Gleicher et al. Reproductive Biology and Endocrinology 2014, 12:63 Page 5 of 12
http://www.rbej.com/content/12/1/63Our evolving approach to “older” ovaries is best demon-
strated in a recently published study of 128 consecutive
infertile women with extremely low FOR, defined by
AMH values below 0.4 ng/m; many, indeed, had undetect-
able AMH levels. Their mean age was 40.8 ± 4.1 years,
their mean baseline FSH was 15.7 ± 11.1 mIU/mL and
their mean AMH was a remarkable 0.2 ± 0.1 ng/mL. Even
this extremely adversely selected patient population
still recorded a 7.9 percent clinical pregnancy (95% CI:
4.9-11.9%) per cycle, and a cumulative pregnancy rate
of 15.6 percent (95% CI: 9.8-23.1%) in up to three con-
secutive IVF cycles. As one would expect, age 42 years
significantly differentiated between better and poorer
pregnancy (P = 0.013) and delivery chances (P = 0.036) [5].
Combining these data, published in 2011 and reflecting
preceding years, with here presented, more recent out-
comes, some interesting additional conclusions relating to
patient age and FOR, as represented by AMH values,
become possible: Likely the most important one is the
relative irrelevance of even extremely low FOR (low
AMH levels) up to and including age 42. Both of these
studies demonstrate very clearly that, even with extremely
low AMH or even undetectable levels, younger women and
older women up to and inclusive of age 42 years, still have
surprisingly good clinical pregnancy and live birth chances
with IVF treatments. With and above age 43 years, a
remarkable further drop off can be observed but serial
cycles, likely, still will allow for decent cumulative returns
up to and inclusive of at least age 45 years [5] and Table 1.
It again is important to reemphasize that here reported
outcomes, because of adverse patient selection, likely,
represent worst case scenarios, and even better outcomes
can be expected in less adversely selected patients of
same ages.
Utilization of high dosage gonadotropin stimulation has
remained controversial. In women pretreated with DHEA,
such an approach, however, does appear effective as larger
oocyte numbers lead to more available euploid embryos
for transfer [21]. This is an important observation since
colleagues who reported that aneuploidy increases with
higher gonadotropin dosages are, likely, correct [22,23].
They, however, overlook that increases in aneuploidy
percentages are more than compensated by increases in
absolute embryo numbers with DHEA supplementation.
Despite increases in percentage of aneuploid embryos
with high gonadotropin stimulations, properly selected
patients, therefore, nevertheless end up with a net benefit
in number of transferrable embryos [21]. Other investiga-
tors concur with these conclusions [24,25].
In older women, we also fail to understand the widely
utilized practice of culturing embryos to blastocyst stage
(days-5/6) since embryos at advanced female ages in the
laboratory only rarely survive to days 5/6. Others share
our opinion on this subject as well [26].Since increasing numbers of IVF centers now, however,
resort to routine blastocyst stage culture, including in
women with low FOR and at advanced ages, we have had
ample opportunities to treat women who failed multiple
such attempts before presenting to our center. Though
not a “controlled” study set up, we in a good number of
such patients succeeded in establishing pregnancies
(reaching normal delivery) who in repeated preceding
cycles either failed to have embryos reach blastocyst
stage and/or failed to reach embryo transfer for other
reasons [27] and Gleicher N, unpublished data. This is
also a reason why we oppose PGS in older women,
when used to improve IVF outcomes [27]. PGS in older
patients actually, for all of above noted reasons, appears to
reduce pregnancy chances in association with IVF [28].
Systematic literature review and discussion
National U.S. aging trends
Figure 2 summarizes national U.S. age distributions for
IVF, reported to the CDC between 1997 and 2010 (Center
for Disease Control and Prevention 2013). Till 2006 CDC
published patient outcome data only up to age 42 years;
since 2007 up to age 44 and, starting in 2010, also includ-
ing women above age 44. In 1997 women under age 35
represented 44.7 percent of all fresh non-donor IVF cycles;
by 2010, however, only 41.4 percent (Table 2 and Figure 2).
Concomitantly, as further evidence for the “graying” of
fertility care in the U.S., the number of donor egg cycles
more than doubled between 1997 and 2010 (Table 2).
Growth in donor egg cycles at our center also exceeded
growth in fresh IVF cycles over the last five years (data
not shown).
As women age, they require earlier utilization of IVF
and higher medication dosages for ovarian stimulation.
Increasing embryo aneuploidy with advancing maternal
age [29], and increasing miscarriage risk [30], together
with higher medication costs, lead to higher treatment
costs per cycle, while efficacy of treatments declines in
parallel [30]. Cost effectiveness of IVF, therefore, decreases
with advancing female age (see also later).
Practically all infertility treatments convert natural,
mono- follicular into poly-follicular cycles, increasing the
risk of multiple births [31]. Older maternal age during
1980-2009 accounted for approximately one-third of the
U.S. increase in twinning [32]. Bamberg et al. reported
34.4 percent of twin pregnancies to be due to infertility
treatments, a 3.2-year increase in maternal mean age over
their study period, more infertile women above age 35
than among spontaneously conceived twins (37.6% vs.
22.9%), and significantly higher mean ages (32.5 vs.
30.1 years) [33].
This development is at least partially driven by advancing
female age and increasing length of infertility increasing the
desire for multiple births [34]. The increasing complexities
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Figure 2 Percentage distribution of U.S. IVF cycles per age groups, years 1997-2010. The figure demonstrates in the young patient groups
(<35 years and 35-37 years) flat IVF cycle years for the period between 1997-2010, and even mild declines, starting in 2006/2006. In contrast, the
oldest patient groups, before 2007 not even registered in national outcome reporting in the U.S., gathered steam. Starting in 2010, national outcome
reporting for the first time, indeed, included women above age 44 years. All of these development also correlate well to reported U.S. data, suggesting
that women above age 40 now represent the, proportionally, most rapidly age group of women having children [1,2].
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entering fertility care, therefore, are multifactorial (see
also later).Limited access to care
The increase in older women pursuing pregnancy is taking
place against a background of considerable skepticism and
even resistance from the U.S. government, the insuranceTable 2 Age distribution of U.S. IVF cycles 1997-2010
Total <35 35-37 38-40
1997 55,042 24,581 (44.7%) 12,733 (23.1%) 10,997 (20.0%
1998 61,650 27,858 (45.2%) 14,146 (23.0%) 12,037 (19.5%
1999 63,123 29,682 (47.0%) 15,291 (24.2%) 12,848 (20.4%
2000 71,556 33,453 (46.8%) 17,284 (24.2%) 14,701 (20.6%
2001 77,102 35,984 (46.7%) 17,791 (23.1%) 16,283 (21.1%
2002 81,888 37,591 (45.9%) 19,110 (23.3%) 17,454 (21.3%
2003 86,753 39,852 (45.9%) 20,056 (23.1%) 18,660 (21.5%
2004 89,535 40,853 (45.6%) 21,019 (23.5%) 19,174 (21.4%
2005 92,405 41,302 (44.7%) 22,624 (24.5%) 19,482 (21.1%
2006 93,866 41,369 (44.1%) 23,376 (24.9%) 19,775 (21.1%
2007 100,592 42,127 (41.9%) 23,504 (23.4%) 20,612 (20.5%
2008 103,104 43,296 (42.0%) 23,326 (22.6%) 21,793 (21.1%
2009 101,090 42,384 (41.9%) 21,860 (21.6%) 22,144 (21.9%
2010 100,824 41,744 (41.4%) 21,369 (21.2%) 21,741 (21.6%industry and many colleagues in the medical community
[30,35,36].
In many European countries advanced age is often
considered a categorical barrier to treatment. For ex-
ample, in the UK coverage is limited to ages 23-39
years [37], though an expansion to age 42 has recently
been proposed [38]. Sweden restricts access to fertility
treatment after age 40-42 years [39], and Finland after
age 40 years [40].41-42 43-44 >44 Donor ETs
) 6,691 (12.2%) 4,498
) 7,609 (12.3%) 5,308
) 5,302 (8.4%) 5,844
) 6,118 (8.6%) 6,731
) 7,044 (9.1%) 7,722
) 7,733 (9.4%) 8,394
) 8,185 (9.4%) 8,970
) 8,487 (9.5%) 9,283
) 8,997 (9.7%) 9,649
) 9,346 (10.0%) 10,049
) 9,535 (9.5%) 4,814 (4.8%) 10,321
) 9,783 (9.5%) 4,907 (4.8%) 10,718
) 9,845 (9.7%) 4,857 (4.8%) 10,151
) 10,122 (10.0%) 4,501 (4.5%) 1,347 (1.3%) 9,866
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services has, therefore, greatly increased amongst older
patients [41,42]. Our own center has witnessed a remark-
able increased in older patients from Scandinavian
countries over recent years, Particularly older Swedish
patients in their country appear to face almost complete
exclusion from access to fertility treatments, including
from private centers. Prohibition of oocyte donation in
many countries further exacerbates need for travel to
receive fertility care [41].
In the U.S., restrictions are often more subtle. Medicaid
and Medicare, the two federally funded government health
care programs, do not offer coverage for IVF. The effects
of the Affordable Care Act (“Obamacare”) on IVF cover-
age are as of this point unpredictable, as is the future of
the whole program, In the private insurance market
age-linked restrictions greatly vary even within different
insurance plans offered by the same insurance companies.
The medical profession, however, also contributes to
some of the resistance in Europe and the U.S. Most fertil-
ity centers on both sides of the Atlantic maintain rigid
age-cut offs and/or link denials of treatment to laboratory
parameters, reflective of FOR. Indirectly, these laboratory
parameters, of course, also reflect age [43], though pa-
tients may be unaware that, for all practical purposes,
age-associated cut-offs are applied.
Our review of available data suggests that such age-
associated restrictions to treatment access lack basis in
evidence since other factors than age also play major
roles in determining pregnancy chances. Indeed what
pregnancy chances are is often incorrectly assessed. For
example, we find that patients frequently are advised
that above age 40 years pregnancy chances from IVF
and intrauterine inseminations (IUI) are similar. They,
therefore, are refused IVF, and instead offered IUI cycles.
Since 2001 the literature, however, suggests that IVF
actually offers clearly superior pregnancy chances and
time to conception at older ages in comparison to IUIs
[44,45].
Many colleagues also routinely advise patients that,
above age 40 - 42 years, IVF live birth rates are in the 1-2%
range. As here presented data demonstrate, such a claim is,
however, likely at least up to and inclusive of age 45 years
unsupported, utilizing contemporary IVF standards of care,
especially if patients are willing to consider consecutive
cycles [5] and Table 1. Where this widely shared opinion
originates is, therefore, unclear.
The most frequent reason for withholding infertility
treatments amongst colleagues has been concern about
cost-effectiveness of such treatments in older women
[43,46]. Other motives, however, can also play a role: For
example, since fertility centers often compete based on
clinical pregnancy and delivery rates, lower pregnancy
chances of older women can drag down a center’s overallIVF outcomes. In the U.S. such considerations are con-
demned by professional guidelines [8].
The obvious economic importance of pregnancy and
delivery rates for IVF center was recently, however, again
demonstrated when a small group of U.S. centers was
reported to manipulate their contributions to the national
outcome reporting system [47] by excluding unfavorable
patients from reporting, either cancelling cycles before
retrieval or avoiding reportable embryo transfers by cryo-
preserving all embryos without attempting a transfer [48].
Motivations for cycle cancellations can also contrib-
ute to outcome reporting biases: Some centers maintain
unrealistic minimum follicle numbers for taking a patient
to egg retrieval; others artificially increase cycle cancella-
tions by routinely culturing embryos of older women’s to
day-5/6 blastocyst-stage instead of transferring on day-3
[26]. A recently increasingly propagated protocol adds
preimplantation genetic screening (PGS) after trophecto-
derm biopsy to routine IVF [49]. In older women only few
embryos, however, usually survive to blastocyst stage,
and even fewer will be euploid. So treated older women
will, therefore, only infrequently reach embryo transfer
and, therefore, escape reporting requirements [26,27,48].
Reported IVF pregnancy and delivery rates in such cases,
therefore, are misleading since they are not calculated by
“intent to treat” (i.e., cycle start) but use as reference point
embryo transfer, which older women, of course, only
rarely achieve.When should treatment be considered futile?
For colleagues concerned about cost effectiveness of IVF
at advanced patient ages, the central question becomes
at what point treatments should be considered futile.
The Ethics Committee of the ASRM defines “futility” as
equal to or less than a one-percent chance of live birth.
A “very poor” prognosis, in contrast, is defined by low
but not nonexistent chances of live births (>1% to ≤5%
per treatment cycle) [8].
Most colleagues providing fertility services on both
sides of the Atlantic, currently, likely, consider almost all
women above age 40-42 to fall into these two patient
categories. Under guidelines from the Ethics Committee
of the ASRM, physicians, therefore, may under such
circumstances refuse treatment of patients. These guide-
lines, however, also recommend that, in case of treatment
refusal, such patients be referred to providers who do offer
treatment to older patients. This, however, rarely, if ever,
happens because affected patients usually are advised
that their only chance of pregnancy is with help of
donor oocytes. As already noted before, the literature
would suggest that this is incorrect advice [5] and
Table 1, and many patients consider oocyte donation
only a second-best choice.
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Our search failed to locate convincing evidence for reli-
able age-specific IVF outcome reports above age 40-42.
Table 3 summarizes limited published data on the subject:
Spandorfer et al. reported on 288 women above age 44 years
(mean 45.4 ± 0.73). Only 161 among them reached retrieval
(clinical pregnancy rate 21.2%, miscarriage rate 85.3%),
resulting in a disappointing live birth rate of only 3.1% [50].
Tsafrir et al. reported pregnancy and delivery rates of
13.9% and 9.1% at age 40, and 2.8% and 0.7% by age
45 years [45], Italian investigators reported a clinical
pregnancy rate of 5.8% in women 40 or older per cycle
start, and 10.5% per transfer [51]. Hourvitz et al. reported
a clinical pregnancy rates per cycle start of 7.7% at age
42, 5.4% at age 43, and 1.9% at age 44, concluding
that IVF should be restricted to under age 43 years [35].
As noted before, reviewing the literature Tsafrir et al.
concluded that IVF, despite low pregnancy rates (<5%),
was preferable to IUI in women above age 40-41 [45].
In 2011 professional societies in Canada published a
whitepaper, which, without quoting pregnancy expecta-
tions, noted that above age 40 IVF should be considered
after only one or two failed cycles of controlled ovarian
stimulation [52].Table 3 Reported pregnancy rates in infertile women
above age 40




Spandorfer et al.1 [50] IVF 21.2 3.1 2007
Tsafrir et al. [45] IUI/IVF 2009
Age 40 13.9 9.1
Age 45 2.8 0.7
Schimberni et al. [51] IVF 2009
Per cycle 5.8
Per transfer 10.5









Age >44 < 4.0
Ninimäki et al. 2 [7] IVF 2012
1 embryo ET 19.5 11.0
2 embryo ET 23.5 13.6
1After reviewing the literature, concluded that after age 40-41 IVF was
preferable to IUI;
2Reflects patients between ages 40-44 years;
ET, embryo transfer.Marinakis and Nikolaou reported live births rates in
the United Kingdom (UK) of 11.0% at ages 40-42, 4.6%
at ages 43-44 and less than 4.0% above age 44 [36]. Soullier
et al. reported delivery rates of 4.0 percent for women
above age 40 [53]. Analyzing 124,148 IVF cycles (33,514 live
births) in the U.K., Lawlor and Nelson reported that two
embryos transfers increased odds of live births at ages 40 or
older more than in younger women, demonstrating that
outcomes in older women can be improved by increasing
embryo numbers transferred [54]. Ninimäki et al. were
outliers in their outcomes, reporting with transfer of
two and one embryo, respectively, pregnancy rates of
23.5 and 19.5 percent and live birth rates of 13,6 and
11.0 percent between ages 40-44 [7].
Skepticism towards treatment of older women is under-
standable, considering such limited and generally low
reported outcome data. Lack of evidence in favor of
treatment should, however, not be misconstrued as
evidence in favor of no treatment.
Available data, therefore, have to be analyzed with cau-
tion. They suggest that: (i) only few centers worldwide
routinely treat older women to IVF cycle completion; (ii)
older patients, therefore, frequently are not given the
opportunity to benefit from current state-of-the-art IVF
treatments; Consequently, (iii) available outcome data
are insufficient. Maybe most importantly, however, (iv)
absence of controlled treatment attempts of older women
with use of their own oocytes prevents improvements in
treatment outcomes of such patients, creating a vicious
circle to the detriment of older women,Patient autonomy
Agreeing with a recently voiced ethical opinion by French
colleagues in association with IVF [55], our center advo-
cates patient autonomy in all decision-making processes
in association with IVF. We fully support the deliberative,
case-by-case approach, advocated by these authors in
allowing patients to reach informed decisions. As part of
this process we see it as our responsibility as physicians, at
all stages, to (i) inform patients in unbiased form about
their options, and (ii) advise patients, based on our own
center’s outcome data, what their chances of treatment
success/failure are with each treatment option. We then
defer to the patients’ decisions, as long as they do not
unreasonably endanger their own wellbeing or that of
their potential offspring(s). Above age 45 years, the
process, therefore, involves extensive medical as well
as psychosocial evaluations of patients.
This approach makes infertility treatments at our center,
in principle, available to almost all patients who are not in
menopause (FSH ≥ 40.0 mIU), and explains the extreme
adverse selection of our center’s patient population, de-
scribed earlier.
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women are emotionally not ready to proceed into oocyte
donation. Often they, first, have to convince themselves
that they have exerted maximal efforts with use of their
own eggs. Advising such women that oocyte donation
represents their only reasonable chance of pregnancy
is, therefore, often not enough. They frequently require
additional cycle attempts with their own ovaries before
reaching a point of conviction that allows them to
proceed with donor eggs.
We consider it appropriate to offer these opportunities,
since women who are prematurely “forced” into egg
donation for the rest of their lives may second-guess
their decision, even if they successfully conceived and
delivered. Indeed, the newborn child may become the
source of this second-guessing, which in rare instances
can lead to significant psychological complications in
the mother/child relationship, even rejection of the
child by the mother (Gleicher N, unpublished data).
Cost-effectiveness
As noted earlier, cost-effectiveness is often the principal
argument against treating older patients [30]. Paradoxically,
this is an argument most prevalent in countries perceived
as “social” in political outlook, like, for example, in the
Scandinavian countries, These countries often do not
consider expenditures on fertility treatments in older
women to meet minimum thresholds of cost effectiveness
[40]. Insurance companies in the United States (U.S.)
have in some states voiced similar arguments in support
of age restrictions in coverage of fertility services or in
opposition to mandated insurance coverage for fertility
services [56,57].
Age-dependent rationing of medical care is a widely
accepted concept in many European countries [40], while
fear of such rationing in the U.S. has been a major reason
for opposition to the recently passed Affordable Care Act
(“Obamacare”) [58]. Defining cost-effectiveness of infertility
care is, therefore, as much an economic as a political issue,
often as much affected by geopolitical considerations as by
pure cost considerations.
The state of Israel is a good example: With the highest
utilization of IVF in the world (1657 IVF cycles/million
citizens/year), this small country performs almost twice
the number of IVF cycles of Iceland, the second highest
utilizing nation [59]. The reason is that the Israeli govern-
ment considers any subsidy of IVF, at almost all ages, “cost-
effective” because population growth is considered essential
to its economic development and national security [60].
This can be contrasted with the Canadian province of
Québec, where the state government only agreed to assume
costs for IVF coverage in return for a commitment by the
local provider community to reduce twin pregnancies
by accepting a single embryo transfer (e-SET) mandate[61]. Québec and Israel’s governments, thus, very obviously,
reached very different “cost-effectiveness” conclusions.
Aside from remaining questions whether twin pregnan-
cies really increase health care costs, considering the loss
of life-long economic benefits from “lost” births in Québec,
one has to wonder whether the province’s decision, indeed,
can be considered “cost-effective” [62].
Objective assessments of cost-effectiveness are further
complicated by the greatly varying methods in how cost-
effectiveness is assessed in different countries. In The
Netherlands, Evers, for example, calculated the lifelong
contribution of every newborn to the growth national
product (GNP) at €1,848,320, while societal costs, includ-
ing childcare, education social welfare and health care
costs add up to only €1,610,000. He concluded that every
birth leaves Dutch society with a net-gain of approxi-
mately €238,320 (US$ ca. 303,000), in his opinion render-
ing the funding of IVF up to age 44 years cost effective
[63]. We are unaware of similar studies in other countries,
and Evers’ calculations for The Netherlands are, of course,
not universally applicable.Further legal and ethical considerations
Whether older women should be afforded a chance of con-
ceiving is also a question with significant legal and ethical
dimensions. Achieving motherhood represents fulfillment
of a most basic human need (Perla L [64]; Smajdor A, [65]).
Not to consider this fact, even in associations with cost-
effectiveness considerations, therefore, appears inhumane.
The concept of universal reproductive rights is based on
the recognition that individuals have the absolute right to
decide freely and responsibly about number, spacing and
timing of their children, free of discrimination (which in-
cludes age-discrimination), coercion and violence (Gender
and reproductive rights home page, 2013).
Like other patients, older women are entitled to ethical
treatment, including autonomy (of decision making), ben-
eficence, non-maleficence and justice. A number of ethicists
have addressed the desire of older women to conceive:
Perla, emphasizes respect for personal patient autonomy
and staff empathy [64]. Smajdor notes that, with IVF repre-
senting medical treatment, it would be unethical to use it
as a means of social control, providing or withholding it on
basis of moral judgments about a patient’s values or her
lifestyle [65].
Delaying childbearing cannot simply be explained by
the public’s ignorance of appreciating the biological
relationship between female aging and female ability to
conceive [66]. Society, therefore, has to accept that the
increase in the number of older women having children
to a significant degree is caused by objective societal
developments, and not the personal fancy of only a few
outliers.
Gleicher et al. Reproductive Biology and Endocrinology 2014, 12:63 Page 10 of 12
http://www.rbej.com/content/12/1/63Effects on pregnancy management
With advancing age women develop increasing numbers
of medical disorders [67]. At least some of these condi-
tions, for example autoimmune diseases, can affect fertility
potential [68,69] and/or raise outcome risks for mothers
and offspring [69-73]. Prospective risk management,
therefore, becomes essential in older women to avoid
preventable pregnancy losses and other complications
at varying gestational stages.
In older women fertility treatments, therefore, require
increased attention to confounding medical problems,
not always easily apparent in routine pre-IVF evaluations.
Testing requirements, therefore, increase, as do consulta-
tions from other medical specialties. Not to be forgotten
are socio-economical evaluations since any desire for
motherhood at advanced age needs to be matched by
social and economic abilities to parent a child, and to
care for the child’s upbringing.
As medical complications are more commonplace in
older women, medical providers, including obstetricians,
perinatologists, neonatologists and consultants from other
medical specialties, have to be ready for an increasing
volume of more complicated pregnancies, [70 = 73]. In-
creasing adverse maternal and neonatal outcomes have
to be expected as a consequence.
These evolving changes have not been appreciated in
full. For example, our medical specialty has largely failed to
recognize the contribution of older women to the increased
numbers of multiple births, mostly twins [31-33], while
concentrating on IVF in criticism [74,75]. Only a very
recently published study for the first time acknowledged
the contribution of an aging infertility population to the
multiple pregnancy issue, following fertility treatments [76].
Putting aside whether twins really represent adverse
outcomes of infertility treatments [77], older women face
different risk/benefit consideration than younger patients.
Almost two decades ago, we for the first time reported on
the strong desire of infertility patients to conceive twins,
which increases with length of infertility and advancing
patient age [34]. Those sentiments should not surprise, as
older women have lower chances and less time to
complete their families. Scotland et al. more recently in a
European patient population noted that patients, there-
fore, are willing to take carefully considered, and educated
risks to compensate for their lower pregnancy chances
[78]. Can older women, therefore, really be blamed for, at
times, making different risk/benefit choices than younger
women?
A brief discussion of our center’s data
We previously noted under materials and methods that
our here presented outcome data in older women have
to be viewed with caution because they were achieved
in a highly adversely selected patient population who,almost uniformly, were on supplementation with DHEA.
Such supplementation has still remained somewhat con-
troversial in its efficacy. While it would exceed the frame-
work of this manuscript to document the rational of this
treatment approach in older women, suffice to say that
our analysis of published data, relying on animal as well as
human data, strongly supports supplementation of older
women with androgens due to a relative hypoandro-
genemia in such patients in comparison to younger ages
[14,15]. A relative recent review of the subject was pub-
lished, to which interested readers are referred [17,18].
Conclusions
Reproductive medicine is inching ever closer towards
technical abilities, which will allow for successful repro-
duction, almost independent of female age. Recent evidence
that sperm and oocytes can be derived from testicular [79]
and ovarian stem cells [80], and that even pluripotent adult
stem cells can be used to produce gametes [81,82], will,
likely, make age-independent human reproduction a
clinical reality within the foreseeable future. If progress
in infertility treatments over the last 10-20 years has
generated a pregnancy boom for women in their 40s,
independence from ovarian and testicular senescence
will expand this boom into the females’ 50s and, maybe,
even 60s.
Societal consequences will be highly significant: With
women’s lifespans in many industrialized countries now
exceeding 80 years, even 50-year old mothers now will
have postmenopausal life expectancies exceeding post-
menarcheal life expectancies of much younger mothers
at the beginning of the 20th Century. Women, therefore,
will increasingly give birth to children at what, just one
to two generations ago, used to be grandparental ages.
Consequences will not only be medical in nature but will
permeate all aspects of modern society. Against a back-
drop of already budget-bursting health care costs, medical
practice and society better get ready for this revolution!
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